Cortexin vs Vasopressin

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Neuropeptide binding V1aR (social behavior/memory, vasoconstriction), V1bR (ACTH/stress), V2R (antidiuretic); enhances hippocampal memory consolidation and social recognition

Vasopressin (arginine vasopressin, AVP) is an endogenous hypothalamic nonapeptide approved in pharmaceutical form for central diabetes insipidus and as a vasopressor in septic shock; it acts through V1a receptors in the vasculature and brain and V2 receptors in the renal collecting duct to regulate blood pressure, water balance, and stress responsiveness. In the central nervous system, vasopressin functions as a neuromodulator involved in social recognition, stress-related memory encoding, and hippocampal synaptic plasticity, with V1a receptor activation in the dentate gyrus facilitating neuronal excitability and long-term potentiation. Preclinical studies document vasopressin-mediated enhancement of LTP in hippocampal circuits, and human neuroimaging research has demonstrated differential effects of intranasal vasopressin on social and memory-related neural activity compared to placebo. Vasopressin is an FDA-approved prescription drug; its use via intranasal delivery for cognitive or behavioral applications is investigational, and clinical evidence for cognitive enhancement in healthy individuals is very limited. Vasopressin vs desmopressin: the selectivity tradeoff Vasopressin's clinical use is primarily in critical care — vasopressin 0.03–0.04 units/minute IV is a standard vasopressor in septic shock and vasodilatory shock refractory to catecholamines, acting through V1a receptors in vascular smooth muscle to increase systemic vascular resistance. For antidiuretic indications (diabetes insipidus, nocturia), desmopressin is used instead of vasopressin because desmopressin's V2-selective action avoids the vasoconstriction, hypertension, and cardiac effects that V1a receptor activation produces. The two compounds should not be used interchangeably for the same indication. Intranasal vasopressin for cognitive and social research: Research interest in intranasal vasopressin for cognitive and social function applications has produced a mixed literature. A well-cited 2019 study (Parker et al., PNAS) found intranasal vasopressin increased social communication in autistic children; a subsequent larger replication trial did not reproduce the finding. For memory enhancement in healthy adults, controlled studies have generally shown no consistent benefit from single-dose intranasal AVP, with vasopressin's cognitive effects mediated by complex V1a receptor signaling in the hippocampus and amygdala that appears state-dependent (most evident in stress contexts). The compound remains a research tool for neuroendocrinology rather than a validated cognitive enhancer, and exogenous intranasal vasopressin is not commercially available in Western markets for this use.